|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Mirum Pharmaceuticals, Inc. (MIRM) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
53,602,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Mirum Pharmaceuticals is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of therapies for rare and orphan diseases. Co.'s focus is the development and commercialization of LIVMARLI® (maralixibat) oral solution (Livmarli) and volixibat. Livmarli is an oral solution approved as a once daily medicine for cholestatic pruritus in patients with Alagille syndrome one year of age and older. Co.'s second product candidate, volixibat, an oral, minimally-absorbed agent designed to inhibit ileal bile acid transporter, for the treatment of adult patients with cholestatic liver diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
4,000 |
4,000 |
175,963 |
175,963 |
Total Buy Value |
$101,200 |
$101,200 |
$4,703,025 |
$4,703,025 |
Total People Bought |
1 |
1 |
2 |
2 |
Total Buy Transactions |
2 |
2 |
8 |
8 |
Total Shares Sold |
4,303 |
26,974 |
69,916 |
431,922 |
Total Sell Value |
$111,017 |
$737,972 |
$1,983,116 |
$9,495,201 |
Total People Sold |
1 |
5 |
6 |
8 |
Total Sell Transactions |
1 |
12 |
21 |
30 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Clements Ian |
Chief Financial Officer |
|
2020-12-23 |
4/A |
B |
$18.65 |
$29,691 |
D/D |
1,592 |
7,871 |
2.74 |
- |
|
Peetz Christopher |
President and CEO |
|
2020-12-23 |
4 |
B |
$18.60 |
$93,480 |
I/I |
5,000 |
201,570 |
2.66 |
- |
|
Clements Ian |
Chief Financial Officer |
|
2020-12-23 |
4 |
B |
$18.55 |
$45,975 |
D/D |
2,470 |
7,841 |
2.74 |
- |
|
Longpre Lara |
Chief Development Officer |
|
2020-11-10 |
4 |
A |
$15.27 |
$12,549 |
D/D |
822 |
75,822 |
|
- |
|
Radovich Peter |
Chief Operating Officer |
|
2020-11-10 |
4 |
A |
$15.27 |
$13,144 |
D/D |
861 |
3,506 |
|
- |
|
Tucker Edwin Jonathan |
Chief Medical Officer |
|
2020-11-10 |
4 |
A |
$15.27 |
$19,464 |
D/D |
1,275 |
32,275 |
|
- |
|
Clements Ian |
Chief Financial Officer |
|
2020-11-10 |
4 |
A |
$15.27 |
$20,930 |
D/D |
1,371 |
5,371 |
|
- |
|
Vig Pamela |
Chief Scientific Officer |
|
2020-11-10 |
4 |
A |
$15.27 |
$9,083 |
D/D |
595 |
2,207 |
|
- |
|
Peetz Christopher |
President and CEO |
|
2020-11-10 |
4 |
A |
$15.27 |
$20,930 |
D/D |
1,371 |
1,371 |
|
- |
|
Tucker Edwin Jonathan |
Chief Medical Officer |
|
2020-10-30 |
4 |
OE |
$7.70 |
$192,500 |
D/D |
25,000 |
31,000 |
|
- |
|
Radovich Peter |
Chief Operating OfficerOfficer |
|
2020-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,645 |
|
- |
|
Tucker Edwin Jonathan |
Chief Medical Officer |
|
2020-03-20 |
4 |
B |
$11.90 |
$29,740 |
D/D |
2,500 |
6,000 |
2.74 |
- |
|
Tucker Edwin Jonathan |
Chief Medical Officer |
|
2020-03-19 |
4 |
B |
$9.91 |
$19,818 |
D/D |
2,000 |
3,500 |
2.74 |
- |
|
Tucker Edwin Jonathan |
Chief Medical OfficerOfficer |
|
2019-10-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
Fischer Laurent |
Director |
|
2019-09-17 |
4 |
B |
$9.37 |
$15,435 |
D/D |
1,648 |
6,750 |
2.39 |
- |
|
Fischer Laurent |
Director |
|
2019-09-16 |
4 |
B |
$9.47 |
$4,280 |
D/D |
452 |
5,102 |
2.31 |
- |
|
Longpre Lara |
CHIEF DEVELOPMENT OFFICER |
|
2019-09-10 |
4 |
B |
$10.64 |
$10,268 |
D/D |
965 |
105,372 |
0.01 |
- |
|
Brege Laura |
Director |
|
2019-09-10 |
4 |
B |
$11.22 |
$112,200 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
Fischer Laurent |
Director |
|
2019-09-10 |
4 |
B |
$10.29 |
$9,881 |
D/D |
960 |
4,650 |
2.39 |
- |
|
Fischer Laurent |
Director |
|
2019-09-09 |
4 |
B |
$10.54 |
$20,992 |
D/D |
1,970 |
3,690 |
2.39 |
- |
|
Peetz Christopher |
President and CEO |
|
2019-09-09 |
4 |
B |
$10.90 |
$48,132 |
I/I |
4,320 |
196,570 |
2.66 |
- |
|
Vig Pamela |
Chief Scientific Officer |
|
2019-09-06 |
4 |
B |
$10.96 |
$17,682 |
D/D |
1,612 |
1,612 |
2.74 |
- |
|
Fischer Laurent |
Director |
|
2019-09-06 |
4 |
B |
$10.71 |
$18,429 |
D/D |
1,720 |
1,720 |
2.39 |
- |
|
Clements Ian |
SVP Finance & Communications |
|
2019-09-06 |
4 |
B |
$11.07 |
$46,039 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
Peetz Christopher |
President and CEO |
|
2019-09-06 |
4 |
B |
$10.91 |
$51,806 |
I/I |
4,750 |
192,250 |
2.66 |
- |
|
191 Records found
|
|
Page 6 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|